Premium
The Pharmacokinetics of Ceftazidime During Hemodiafiltration in Critically Ill Patients
Author(s) -
Sato Toshihide,
Okamoto Kazufumi,
Kitaura Minoru,
Kukita Ichiro,
Kikuta Koichi,
Hamaguchi Masamichi
Publication year - 1999
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.1999.06218.x
Subject(s) - ceftazidime , pharmacokinetics , medicine , critically ill , elimination rate constant , arterial blood , anesthesia , serum concentration , pharmacology , biology , volume of distribution , genetics , bacteria , pseudomonas aeruginosa
We studied the pharmacokinetics of ceftazidime in 3 critically ill patients undergoing continuous hemodiafiltration (CHDF). Blood samples were obtained from both the arterial and venous sites of the CHDF system 0, 1, 2, 4, 6, and 12 h after the start of ceftazidime administration. Pharmacokinetic variables were calculated by fitting individual concentration‐time curves to a two‐compartment open model. The elimination phase half‐life was 6.86 h, and the total elimination rate constant was 0.17 h −1 . Six hours after the start of administration, the ceftazidime concentration in the arterial site decreased from the peak level of 77.5 ± 31.4 (mean ± standard deviation [SD]) μg/ml to 26.2 ± 2.5 μg/ml. The ceftazidime concentration examined in 2 cases decreased to 14.7 ± 5.8 μg/ml after 12 h. The results suggested that ceftazidime should be administered at 1 g/day in patients with severe infection during CHDF.